Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Today's Market: Is Tech Really Facing Problems At These Levels?

"Merrill Lynch reportedly says Afrezza's potential as a complement to oral in the Type 2 market is uncertain. "

Are they saying this because of weight gain and hypos? Does this really override the benefits of reduced a1c?

Share
New Message
Please login to post a reply